CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • ABVC Dashboard
  • Financials
  • Filings
  • ETFs
  • Institutional
  • Shorts
  • News
  • Reddit

ABVC BioPharma (ABVC)

Company Profile
ABVC BioPharma is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.
ABVC BioPharma logo

Company profile

Ticker
ABVC
Exchange
NASDAQ
Website
abvcpharma.com
CEO
Howard Doong
Employees
Incorporated
Nevada
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
American BriVision (Holding) Corp, Ecology Coatings, Inc., ECOLOGY COATINGS, INC., METU BRANDS, INC., OCIS CORP
SEC CIK
0001173313
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
IRS number
260014658

ABVC stock data

Latest filings (excl ownership)
View all
424B4
Prospectus supplement with pricing info
15 Nov 22
424B3
Prospectus supplement
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Changes in Registrant's Certifying Accountant
21 Oct 22
8-K
ABVC Biopharma Announces Letter to Shareholders
13 Sep 22
8-K
Departure of Directors or Certain Officers
9 Sep 22
424B4
Prospectus supplement with pricing info
25 Aug 22
424B3
Prospectus supplement
25 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Latest ownership filings
View all
3
Shuling Jiang
12 Jul 22
SC 13D
Jiang Shuling
12 Jul 22
3
Chihliang An
31 Mar 22
3
Norimi Sakamoto
10 Dec 21
3
Yoshinobu Odaira
10 Dec 21
3
Tsung Shann Jiang
15 Nov 21
3
Shin-Yu Miao
15 Nov 21
3
Shih-Chen Tseng
15 Nov 21
3
Eugene Jiang
15 Nov 21
3
Chang-Jen Jiang
15 Nov 21

Financial summary

Financial statements Chart ABVC financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.97 mm 1.97 mm 1.97 mm 1.97 mm 1.97 mm 1.97 mm
Cash burn (monthly) 543.03 k 206.64 k 1.26 mm 1.54 mm 171.23 k 788.49 k
Cash used (since last report) 2.28 mm 869.09 k 5.29 mm 6.48 mm 720.19 k 3.32 mm
Cash remaining -313.79 k 1.10 mm -3.32 mm -4.51 mm 1.25 mm -1.35 mm
Runway (months of cash) -0.6 5.3 -2.6 -2.9 7.3 -1.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2022

ABVC institutional ownership history Ownership history
4.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 5 4 +25.0%
Opened positions 3 0 NEW
Closed positions 2 1 +100.0%
Increased positions 0 1 EXIT
Reduced positions 0 2 EXIT
13F shares Current Prev Q Change
Total value 1.66 mm 1.17 mm +41.8%
Total shares 1.56 mm 427.79 k +265.3%
Total puts 0.00 0.00
Total calls 0.00 0.00
Total put/call ratio – – –
Largest owners Shares Value Change
Armistice Capital 1.09 mm $1.16 mm NEW
Vanguard 375.14 k $398.00 k 0.0%
Geode Capital Management 49.92 k $52.00 k 0.0%
BLK Blackrock 39.04 k $41.00 k NEW
Tower Research Capital 6.00 k $6.00 k NEW
Proequities 0.00 $0.00
Largest transactions Shares Bought/sold Change
Armistice Capital 1.09 mm +1.09 mm NEW
BLK Blackrock 39.04 k +39.04 k NEW
Tower Research Capital 6.00 k +6.00 k NEW
MS Morgan Stanley 0.00 -1.46 k EXIT
UBS UBS Group AG - Registered Shares 0.00 -1.27 k EXIT
Vanguard 375.14 k 0.00 0.0%
Proequities 0.00 0.00
Geode Capital Management 49.92 k 0.00 0.0%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented At 2023 APSARD Conference
19 Jan 23
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
6 Jan 23
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 Jan 23
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
6 Jan 23
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations
5 Jan 23

Press releases

From Benzinga Pro
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
19 Jan 23
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
Thinking about buying stock in Bellerophon Therapeutics, Orchard Therapeutics, ABVC Biopharma, KE Holdings, or Vivos Therapeutics?
5 Jan 23
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLPH, ORTX, ABVC, BEKE, and VVOS.
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
17 Nov 22
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
14 Nov 22
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
7 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn